Traders Purchase Large Volume of Zentalis Pharmaceuticals Call Options (NASDAQ:ZNTL)

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock investors bought 2,113 call options on the company. This is an increase of approximately 571% compared to the typical daily volume of 315 call options.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ZNTL shares. Guggenheim reduced their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating on the stock in a research report on Friday, November 15th. UBS Group dropped their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a report on Tuesday. HC Wainwright dropped their price objective on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a "buy" rating for the company in a report on Wednesday. Wedbush restated a "neutral" rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Finally, Wells Fargo & Company lowered their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating for the company in a research note on Thursday. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $8.24.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Barclays PLC boosted its stake in Zentalis Pharmaceuticals by 18.5% during the 3rd quarter. Barclays PLC now owns 75,395 shares of the company's stock worth $277,000 after purchasing an additional 11,748 shares during the period. GSA Capital Partners LLP lifted its stake in shares of Zentalis Pharmaceuticals by 138.5% in the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company's stock worth $2,240,000 after acquiring an additional 353,384 shares during the period. Verition Fund Management LLC lifted its stake in shares of Zentalis Pharmaceuticals by 172.1% in the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company's stock worth $5,536,000 after acquiring an additional 951,500 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Zentalis Pharmaceuticals by 152.6% in the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company's stock worth $2,706,000 after acquiring an additional 399,745 shares during the period. Finally, Primecap Management Co. CA lifted its stake in shares of Zentalis Pharmaceuticals by 21.6% in the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company's stock worth $5,513,000 after acquiring an additional 265,690 shares during the period.

Zentalis Pharmaceuticals Stock Down 12.2 %

Shares of NASDAQ:ZNTL traded down $0.23 during trading on Thursday, reaching $1.66. 3,656,997 shares of the company's stock traded hands, compared to its average volume of 2,910,479. Zentalis Pharmaceuticals has a fifty-two week low of $1.66 and a fifty-two week high of $18.07. The firm has a market cap of $118.29 million, a PE ratio of -0.67 and a beta of 1.86. The company has a 50-day simple moving average of $3.00 and a 200-day simple moving average of $3.30.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.36. On average, equities research analysts forecast that Zentalis Pharmaceuticals will post -2.48 EPS for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.